Table 1.

Baseline demographics of patients included in the analysis

Patient	Age (years)	Sex	Ethnicity	MGFA class	Thymectomy	Therapy at eculizumab initiation
1	45	F	White	IIa	Yes	Prednisone 35 mg/day + pyridostigmine 60 mg TID + IVIg 1g/kg q4w + mycophenolate mofetil 1000 mg BID
2	36	F	White	IIIa	Yes	Prednisone 30 mg/day + pyridostigmine 60 mg TID + azathioprine 200 mg/day
3	56	M	White	IIIb	Yes	Prednisone 40 mg/day + mycophenolate mofetil 1000 mg BID + pyridostigmine 60 mg TID
4	72	M	White	IIa	No	Prednisone 40 mg/day + mycophenolate mofetil 1000 mg BID + pyridostigmine 60 mg TID
5	65	F	White	IIb	No	IVIg 1g/kg q4w + pyridostigmine 60 mg TID + prednisone 30 mg/day
6	26	F	White	IIIa	Yes	IVIg 1g/kg q4w + prednisone 40 mg/day + pyridostigmine 60 mg TID
7	66	M	White	IIb	No	Prednisone 30 mg/day + mycophenolate mofetil 1000 mg BID + pyridostigmine 60 mg TID
8	38	F	White	IIa	No	Prednisone 40 mg/day + mycophenolate mofetil 1500 mg BID + pyridostigmine 60 mg TID
9	30	F	White	IIb	Yes	Prednisone 20 mg/day + mycophenolate mofetil 1500 mg BID + pyridostigmine 60 mg TID
10	60	M	White	IIa	No	Prednisone 40 mg/day + azathioprine 200 mg/day + pyridostigmine 60 mg TID
11	61	F	Black	IIIb	Yes	IVIg 1g/kg q5w + prednisone 30 mg/day + pyridostigmine 60 mg TID
12	38	F	White	IIIa	Yes	IVIg 1g/kg q4w + prednisone 20 mg/day + pyridostigmine 60 mg TID
13	24	F	White	IIIa	Yes	IVIg 1g/kg q4w + prednisone 45 mg/day + pyridostigmine 60 mg TID + mycophenolate mofetil 1000 mg BID
14	43	M	White	IIb	Yes	Prednisone 40 mg/day + pyridostigmine (dose unknown)
15	51	M	White	IIa	No	Prednisone 40 mg/day + pyridostigmine 60 mg TID + mycophenolate mofetil 1000 mg BID

BID, twice daily; F, female; IVIg, intravenous immunoglobulin; M, male; MGFA, Myasthenia Gravis Foundation of America; qnw, every n weeks; TID, three times daily.